Aurealis Therapeutics submits Clinical Trial Application for AUP-16 Phase 1 DFU study

Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application (CTA) to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in a first-in-human phase 1-2A clinical study as treatment of […]